Pliszka 2000.

Methods	Single‐center, randomized, double‐blind, placebo‐controlled, parallel‐group trial Country: United States Number of study sites: 1 Statistical methods: modified ITT (last observation carried forward)
Participants	Sample size: 59* children/adolescents with an ADHD diagnosis according to the Diagnostic Interview Schedule for Children Dropouts: 5 Psychiatric comorbid disorders: oppositional defiant disorder, conduct disorder, anxiety Age range: 6 years to 10 years Mean age (SD): 8.2 (1.6) years Sex: NR ADHD subtype: NR
Interventions	Three interventions (58 children/adolescents participated in one of three interventions): Mixed amphetamine salts (short acting), weight‐based, titrated dosing (maximum dose for children < 27.2 kg (60 lbs) was 15 mg/day; maximum daily dose for children/adolescents > 27.2 kg (60 lbs) was 30 mg/day), (n = 20) Methylpehnidate, weight‐based, titrated dosing (maximum dose for children < 27.2 kg (60 lbs) was 25 mg/day; maximum daily dose for children/adolescent > 27.2 kg (60 lbs) was 50 mg/day), (n = 20) Placebo (n = 18) Duration: 21 days
Outcomes	Relevant outcomes: ADHD core symptom severity, assessed with IOWA (inattention/overactivity with aggression) Conners' Teacher Rating Scale and Conners' Parent Global Index Clinical impression, assessed with Clinical Global Impressions ‐ Improvement scale Number of participants who dropped out due to any adverse event Adverse events Other outcomes: Agression/defiance, assessed with Conners' Teacher Rating Scale
Notes	ClinicalTrials.gov identifier: not available Author's affiliation: university and pharmaceutical industry Study funding: pharmaceutical industry *1 participant dropped out before the end of the study, and was not accounted for in the participant characteristic description (data only provided on 58 participants)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Method of allocation concealment not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low attrition (10%), and reasons provided. All randomized children/adolescents included in primary analysis
Selective reporting (reporting bias)	Unclear risk	Study protocol not available and the possibility of reporting bias could not be assessed
Other bias	Low risk	Study appears to be free of other biases
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Intervention and placebo are described as identical
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blinding of outcome assessment not described